Asklepios BioPharmaceutical, Inc. (AskBio)’s Post

🇬🇧 ⚠️☠️ #TALC is a probable carcinogen ⚠️☠️ Thus defined by the IARC - International Agency for Research on Cancer / World Health Organization, which has placed it within #group2A of the risk classification, the second highest level of certainty that a substance can cause tumors. The analyses were conducted by a group of 29 international experts from 13 countries, who carefully evaluated all available scientific literature. The experts have assessed talc as #probably #carcinogenic to humans (group 2A) based on #limited #evidence (for ovarian cancer) in humans, #sufficient #evidence in laboratory animals, and #strong mechanistic #evidence in primary human cells and experimental systems. The use of talc could have health effects, especially in clinical and industrial settings, particularly during the extraction and processing of the mineral. However, the general population could also be at risk through ingestion, inhalation, or cutaneous and perineal exposure. Talc, in fact, can be used for body care or in cosmetic, pharmaceutical, and food products. In the USA, Johnson & Johnson (J&J) has been involved in numerous legal cases related to the use of baby talc, accused of containing traces of asbestos and causing ovarian cancer and mesothelioma. The company, while continuing to deny the correlation between its product and cancer, has agreed to pay $6.5 billion to settle most of these cases and has withdrawn talc from the North American market. What is the situation in Europe and Italy? We at FiDeAL are ready to discuss and collaborate with those who care about this issue and want to consider an action.

Cracking the EMA Code: Week 4 – Drug Repurposing for Rare Diseases In our final instalment of "Cracking the EMA Code," releasing June 25th, rare disease expert Keith Williams explores the potential of drug repurposing in Europe. Learn how this approach: 💚 Addresses unmet needs of patients 💚 Accelerates development of safer, effective treatments 💚 Navigates market access, pricing, & regulatory hurdles Independent Article, June 27th: Professor Boris Kramer delves into the transformative potential of cell therapies for rare diseases in Europe, highlighting: 💛 Personalized treatment for rare genetic diseases 💛 Overcoming challenges of traditional pharmaceuticals 💛 European regulatory considerations for cell therapies Contact us to explore how our expertise can accelerate your path to making a meaningful difference in the lives of patients. https://lnkd.in/gRJHVmnZ #RareDisease #DrugRepurposing #CellTherapy #EMA

During February's #RareDiseaseDay, we take a look at rare diseases and development efforts in the Asia Pacific region. Drug developers have recognized the transformative potential of developing treatments that can address unmet medical needs and improve outcomes for people living with a rare disease. #DYK there are… • 300 million people living with a rare disease worldwide • 10,000+ distinct rare and genetic disorders • 72% of rare diseases are genetic • 70% of those genetic rare diseases start in childhood • 1 in 10 people are affected by rare disease • 4.8 years → the average time it takes for rare disease patients to receive accurate diagnosis • 95% of rare diseases lack an FDA approved treatment Our team at Fortrea has been honored to serve several biotech and pharmaceutical sponsors, provide insightful guidance and support investigators with rare disease clinical trials in China and across APAC. #APAC #RareDiseases #ClinicalTrials #ClinicalResearch #ShareYourColors #ShowYourRare

𝐎𝐫𝐩𝐡𝐚𝐧 𝐃𝐫𝐮𝐠𝐬: 𝐀𝐧 𝐄𝐱𝐩𝐥𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐚𝐧𝐝 𝐈𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐌𝐞𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐞𝐝 𝐟𝐨𝐫 𝐭𝐡𝐞𝐢𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭.   Unpacks the realm of rare diseases and the remarkable progress achieved in the development of orphan drugs. It zeroes in on these exceptional conditions and their life-altering effect on individuals who grapple with them. It underscores the pivotal role of orphan drugs and their transformative contribution to medicine, particularly in tackling conditions that would otherwise be insurmountable.   Take a moment to read our article for more such valuable insights - https://lnkd.in/g4FuPzbA #orphandrugs #raredisease #marketresearch #wissenresearch

🌟 Exploring the Friedreich Ataxia (FRDA) landscape! Friedreich’s Ataxia (FRDA) is a rare, progressive genetic disorder that usually begins between ages 10 and 15. It leads to a gradual decline in coordination, muscle strength, and endurance. As the condition progresses, many individuals rely on wheelchairs. 📊 Dive into our latest report on FRDA: Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape. https://lnkd.in/g3UbWhQk #FRDA #RareDisease #ClinicalTrials #HealthcareInnovation #DrugDevelopment 

We take a look at rare diseases and development efforts in the Asia Pacific region. Drug developers have recognized the transformative potential of developing treatments that can address unmet medical needs and improve outcomes for people living with a rare disease. #DYK there are… • 300 million people living with a rare disease worldwide • 10,000+ distinct rare and genetic disorders • 72% of rare diseases are genetic • 70% of those genetic rare diseases start in childhood • 1 in 10 people are affected by rare disease • 4.8 years → the average time it takes for rare disease patients to receive accurate diagnosis • 95% of rare diseases lack an FDA approved treatment Our team at Fortrea has been honored to serve several biotech and pharmaceutical sponsors, provide insightful guidance and support investigators with rare disease clinical trials in China and across APAC. #APAC #RareDiseases #ClinicalTrials #ClinicalResearch #ShareYourColors #ShowYourRare

Breaking News in AML Treatment, as Daiichi Sankyo, Inc. Quizartinib Gets the Green Light! 🌟 Fantastic news from the UK's MHRA! 🇬🇧 A game-changer has arrived in the battle against acute myeloid leukaemia - quizartinib (Vanflyta) is now authorised for marketing for adults with a FLT3-ITD mutation as a first-line treatment. This marks an optimistic milestone in the quest to outsmart AML 📈 What does it mean for patients? Once-daily oral quizartinib, combined with chemotherapy, offers new hope, targeting tyrosine kinases to impede the growth of malignant bone marrow cells. In a rigorous Phase III trial, the difference was clear - those on quizartinib witnessed a median overall survival of nearly 32 months versus just 15 months for placebo 💊 The green light by the MHRA is not just approval; it's a beacon of hope for many. Here's to a future where survival is not a matter of chance, but a standard we strive to elevate. Let's continue to rally behind all those dedicated to turning the tide against AML ✅💪 #DaiichiSankyo #Quizartinib #AcuteMyeloidLeukaemia #AML #HealthcareInnovation #ClinicalResearch #ClinicalTrials #Biotechnology #LifeScience #ElixirAssociates #StaffingPartner

We take a look at rare diseases and development efforts in the Asia Pacific region. Drug developers have recognized the transformative potential of developing treatments that can address unmet medical needs and improve outcomes for people living with a rare disease. #DYK there are… • 300 million people living with a rare disease worldwide • 10,000+ distinct rare and genetic disorders • 72% of rare diseases are genetic • 70% of those genetic rare diseases start in childhood • 1 in 10 people are affected by rare disease • 4.8 years → the average time it takes for rare disease patients to receive accurate diagnosis • 95% of rare diseases lack an FDA approved treatment Our team at Fortrea has been honored to serve several biotech and pharmaceutical sponsors, provide insightful guidance and support investigators with rare disease clinical trials in China and across APAC. #APAC #RareDiseases #ClinicalTrials #ClinicalResearch #ShareYourColors #ShowYourRare

During February's #RareDiseaseDay, we take a look at rare diseases and development efforts in the Asia Pacific region. Drug developers have recognized the transformative potential of developing treatments that can address unmet medical needs and improve outcomes for people living with a rare disease. #DYK there are… • 300 million people living with a rare disease worldwide • 10,000+ distinct rare and genetic disorders • 72% of rare diseases are genetic • 70% of those genetic rare diseases start in childhood • 1 in 10 people are affected by rare disease • 4.8 years → the average time it takes for rare disease patients to receive accurate diagnosis • 95% of rare diseases lack an FDA approved treatment Our team at Fortrea has been honored to serve several biotech and pharmaceutical sponsors, provide insightful guidance and support investigators with rare disease clinical trials in China and across APAC. #APAC #RareDiseases #ClinicalTrials #ClinicalResearch #ShareYourColors #ShowYourRare

During February's #RareDiseaseDay, we take a look at rare diseases and development efforts in the Asia Pacific region. Drug developers have recognized the transformative potential of developing treatments that can address unmet medical needs and improve outcomes for people living with a rare disease. #DYK there are… • 300 million people living with a rare disease worldwide • 10,000+ distinct rare and genetic disorders • 72% of rare diseases are genetic • 70% of those genetic rare diseases start in childhood • 1 in 10 people are affected by rare disease • 4.8 years → the average time it takes for rare disease patients to receive accurate diagnosis • 95% of rare diseases lack an FDA approved treatment Our team at Fortrea has been honored to serve several biotech and pharmaceutical sponsors, provide insightful guidance and support investigators with rare disease clinical trials in China and across APAC. #APAC #RareDiseases #ClinicalTrials #ClinicalResearch #ShareYourColors #ShowYourRare